

Solid Tumour Section

Mini Review

Thyroid: Anaplastic (undifferentiated) carcinoma

Sai-Ching Jim Yeung

The University of Texas M. D. Anderson Cancer Center, Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, Department of Endocrine Neoplasia and Hormonal Disorders, 1515 Holcombe Boulevard, Unit 437, Houston, Texas 77030, USA

Published in Atlas Database: Update -November 2007

Online updated version: <http://AtlasGeneticsOncology.org/Tumors/AnaCarciThyroidID5069.html>
DOI: 10.4267/2042/38616

This article is an update of: Fadare O, Tallini G.. Thyroid: Anaplastic (undifferentiated) carcinoma. *Atlas Genet Cytogenet Oncol Haematol.*2003;7(3):190-192.

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2008 *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

Identity

Note: Anaplastic (undifferentiated) carcinoma of the thyroid gland is a highly malignant tumor composed in part or wholly by undifferentiated malignant cells.

Clinics and pathology

Epidemiology

Anaplastic (undifferentiated) carcinoma of the thyroid gland is uncommon, accounting for less than 5% of all cases of thyroid carcinoma. The average age at diagnosis was 66.5 years, with a female to male ratio of 3.1:1 in one study of 70 cases.

Clinics

Most patients are euthyroid with a history of a rapidly enlarging neck mass. Sometimes, the tumor presents as a new-onset thyroid enlargement in a patient with longstanding thyroid nodule(s) or as the recurrence of a well-differentiated thyroid carcinoma. Tumor infiltration of surrounding structures results in secondary symptoms (dyspnea, dysphonia, dysphagia).

Pathology


Tumors are poorly defined, fleshy masses with areas of necrosis and hemorrhage. Microscopically they are composed of anaplastic cells with marked cytologic atypia and high mitotic activity. Tumor necrosis and vascular invasion are common. About one-third of cases of anaplastic thyroid carcinoma (ATC) have coexisting areas of well-differentiated thyroid carcinoma, supporting the hypothesis that ATC arises from well-differentiated thyroid carcinoma.

Histologic patterns include spindle, giant and squamoid cell types. Other patterns (e.g. angiomatoid, carcinosarcoma, lymphoepithelioma-like, adenosquamous) have been described. Undifferentiated (anaplastic) carcinoma of the thyroid must be differentiated from other high grade tumors with similar microscopic appearance originating from adjacent structures in the neck (e.g. larynx). Sometimes this distinction is only possible on clinical/anatomical grounds.

Immunohistochemically, undifferentiated thyroid carcinoma is generally negative for thyroglobulin and calcitonin. Pankeratin and epithelial membrane antigen (EMA) are positive in about one-half and one-third of cases respectively. Vimentin is positive in about 90%, and epithelial membrane antigen is positive in about 30% of cases. Thyroid transcription factor-1 (TTF-1) staining is present in 0-50% of cases. Although immunostaining is negative for muscle-specific actin, Factor VIII-related antigen, and desmin, these markers can differentiate ATC from some soft tissue sarcomas with which they can be confused.

Treatment

No effective treatment modalities are currently available. A few patients with resectable disease have been reported to have long-term survival with aggressive multimodal therapy that included surgery, radiation, and chemotherapy. Current clinical practice emphasizes the use of multimodal therapy to achieve local disease control and stabilization of airway patency. Radiotherapy may be hyperfractionated and in combination with chemotherapy. Chemotherapy is usually doxorubicin-based or taxane-based combinations. Preclinical studies using human ATC



Anaplastic (undifferentiated) thyroid carcinoma is a highly malignant tumor composed by undifferentiated malignant cells. The inset in the left lower corner shows a magnified view of a cell in metaphase of mitosis.

cell lines show promise that new effective combinations including novel drugs will be found in the future.

Prognosis

Anaplastic (undifferentiated) carcinomas are highly aggressive neoplasms that are usually widely invasive at presentation. Regional and distant metastases are common, and about 75% of patients have distant metastasis in the course of their disease. Most patients die within 1 year of the diagnosis with a median survival of 3 to 6 months. The 5-year survival rate is around 5%, and the surviving cases are typically small tumors confined to the thyroid amenable to local resection.

Cytogenetics

Cytogenetics morphological

Anaplastic (undifferentiated) carcinoma represents not only morphologically but also in terms of somatic genetic alterations the extreme malignant form of thyroid cancer and as such it is characterized by complex chromosomal alterations. DNA aneuploidy is present in over 65% of the tumors.

Cytogenetics molecular

LOH: Allelic loss has been identified at 1q (40%), 9p (58%), 11p (33%), 11q (33%), 17p (44%), 17q (43%), 19p (36%), 22q (38%).

CGH: DNA unbalance can be demonstrated at a variety of chromosomal loci in 80% of undifferentiated carcinomas with a median number of chromosomal losses or gains of 10 per case with abnormal CGH profile. Gains were more common than DNA losses. Loss of chromosomal DNA was identified at 1p, 2q, 4q, 5q, 6q, 8p, 13q, 22q. Specific chromosomal DNA alterations (i.e. 3p13-14+, 5q11-31-, 11q13+) may be associated with the transition from more differentiated phenotypes to ATC.

CGH shows frequent gain of 20q, including the UBCH10 gene in 20q13.12, which may also be associated with progression of differentiated thyroid cancers to ATC.

Using microarray-based CGH with further fluorescence in situ hybridization (FISH) analysis, the MAP kinase phosphatase-8 (DUSP26) gene, which codes for a phosphatase that inhibits p38-mediated apoptosis, is shown to be amplified in ATC.

Genes involved and Proteins

Note: The genetic mechanisms involved with the development of anaplastic thyroid cancer are complex. Mutational inactivation of p53 has been identified in 70-80% of anaplastic carcinomas while H-Ras, K-Ras, or N-Ras activating mutations are present in approximately 50% of the cases. BRAF V600E mutation is found in 20% to 25% of cases. PTEN mutations are present in 6%. PIK3CA kinase domain mutations are found in 14%. PIK3CA gene copy amplification is present in 39%.

Aberrant Wnt/beta-Catenin signaling appears to be a distinctive feature of ATC since stabilizing mutations and/or aberrant beta-Catenin nuclear localization are present in 80% of ATC. beta-Catenin nuclear localization is accompanied by its cellular redistribution with marked decrease of the beta-Catenin membrane bound fraction.

ATC are characterized by increased cell replication and high Ki67/Mib1 proliferation index, loss of the apoptotic protein bcl-2 and of Fas and its ligand (usually highly expressed in well differentiated thyroid tumors), by an increase in the proapoptotic protein Bax, by Cyclin D1 over-expression and conversely by a fall in the CDK inhibitor p27. Transmembrane protein 34 (TMEM34) is down-regulated in ATC. It is not clear whether these changes represent the cause or (more likely) the effect of dysregulated cell differentiation and growth in ATC.

Immunohistochemical staining of a tissue microarray of 32 cases of ATC showed the following: beta-catenin (positive in 41% of the cases), aurora A (41%), cyclin E (67%), cyclin D1 (77%), and EGFR (84%).

Thyroglobulin, Bcl-2, MIB-1, E-cadherin, and p53, beta-catenin, topoisomerase II-alpha, and vascular endothelial growth factor are observed to change during progression from differentiated thyroid cancer to ATC.

References

- Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma: a study of 70 cases. *Am J Clin Pathol* 1985;83:135-158.
- Klemi PJ, Joensuu H, Eerola E. DNA aneuploidy in anaplastic carcinoma of the thyroid gland. *Am J Clin Pathol* 1988;89(2):154-159.
- Stringer BM, Rowson JM, Parkar MH, Seid JM, Hearn PR, Wynford-Thomas D, Ingemansson S, Woodhouse N, Goyns MH. Detection of the H-RAS oncogene in human thyroid anaplastic carcinomas. *Experientia* 1989;45(4):372-376.
- Jenkins RB, Hay ID, Herath JF, Schultz CG, Spurbeck JL, Grant CS, Goellner JR, Dewald GW. Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. *Cancer* 1990;66:1213-1220.
- Venkatesh YS, Ordóñez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. *Cancer* 1990;66(2):321-330.
- Ordóñez NG, el-Naggar AK, Hickey RC, Samaan NA. Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. *Am J Clin Pathol* 1991;96(1):15-24.
- Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. *Atlas of tumor Pathology*, 3rd series, fascicle 5 1992.
- Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. *J Clin Invest* 1993;91:1753-1760.
- Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. *J Clin Invest* 1993;91(1):179-184.
- Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsusuka F, Monden M. Treatment of 37 patients with anaplastic carcinoma of the thyroid. *Head and Neck* 1995;18:36-41.
- Capella G, Matias-Guiu X, Ampudia X, De Leiva A, Perucho M, Prat J. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. *Diagn Mol Pathol* 1996;5(1):45-52.
- Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H. DNA copy number changes in thyroid carcinoma. *Am J Pathol* 1999;154:1539-1547.
- Husmark J, Heldin NE, Nilsson M. N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. *Int J Cancer* 1999;83(5):692-699.
- Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML. Downregulation of p27KIP1 and Ki67/Mib1 labelling index support the classification of thyroid carcinoma into prognostically relevant categories. *Am J Surg Pathol* 1999;23:678-685.
- Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. *Thyroid* 2000;10(7):587-594.
- Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. *Genes Chromosomes and Cancer* 2000;27:244-251.
- Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta catenin dysregulation in thyroid neoplasms: down regulation, aberrant nuclear expression and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. *Am J Pathol* 2001;158:987-996.
- Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. *Cancer Res* 2002;62:3408-3416.
- Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao, PH, Singh B. Genome-wide appraisal of thyroid cancer progression. *Am J Pathol* 2002;161:1549-1556.
- Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, Bhakta S, Lavertu P, Ortiz J, Remick S. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). *Journal of Clinical Oncology* 2006;24:300S-300S.
- Akaishi J, Onda M, Okamoto J, Miyamoto S, Nagahama M, Ito K, Yoshida A, Shimizu K. Down-regulation of an inhibitor of cell

growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer. *J Cancer Res Clin Oncol* 2007;133:213-218.

Fury MG, Solit DB, Su YB, Rosen N, Sirotinak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2007;59:467-475.

Lee JJ, Foukakis T, Hashemi J, Grimelius L, Heldin NE, Wallin G, Rudduck C, Lui WO, Höög A, Larsson C. Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. *Thyroid* 2007;17:289-301.

Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. *Thyroid* 2007 Nov 6;[Epub ahead of print].

Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. PI3K/Akt and Ras/Raf-MAPK pathway mutations in anaplastic thyroid cancer. *J Clin Endocrinol Metab* 2007 Nov 7;[Epub ahead of print].

Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A. BRAF V600E mutation in anaplastic thyroid carcinomas and their

accompanying differentiated carcinomas. *Br J Cancer* 2007;96:1549-1553.

Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. *Arch Surg* 2007;142:717-727; discussion 727-729.

Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. *Ann Surg Oncol* 2007;14:719-729.

Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. *Oncogene* 2007;26:1178-1187.

This article should be referenced as such:

Yeung SCJ. Thyroid: Anaplastic (undifferentiated) carcinoma. *Atlas Genet Cytogenet Oncol Haematol*.2008;12(6):477-480.
